# 131I-IPA and Concurrent XRT in Recurrent GBM

> **NCT03849105** · PHASE1,PHASE2 · COMPLETED · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 10 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **RADIATION:** 4-L-[131I]iodo-phenylalanine (131I-IPA)

## Key facts

- **NCT ID:** NCT03849105
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03849105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03849105, "131I-IPA and Concurrent XRT in Recurrent GBM". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03849105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*